Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The purpose of the escalation part of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (if reached) as well as establish the safety profile of epcoritamab in patients with R/R CLL. In the expansion part additional patients will be treated with epcoritamab ...
The purpose of the escalation part of the trial is to determine the recommended phase 2 dose (RP2D) and the maximum tolerated dose (if reached) as well as establish the safety profile of epcoritamab in patients with R/R CLL. In the expansion part additional patients will be treated with epcoritamab at the RP2D and the the purpose is to assess and evaluate the preliminary efficacy, safety and tolerability profiles of epcoritamab at the RP2D.
Tracking Information
- NCT #
- NCT04623541
- Collaborators
- AbbVie
- Investigators
- Not Provided